Neogenomics Stock Gross Profit

NEO Stock

USD 14.03 0.13 0.92%

NeoGenomics fundamentals help investors to digest information that contributes to NeoGenomics' financial success or failures. It also enables traders to predict the movement of NeoGenomics Stock. The fundamental analysis module provides a way to measure NeoGenomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeoGenomics stock.

	Last Reported	Projected for Next Year
Gross Profit	244.6 M	256.8 M
Gross Profit Margin	0.41	0.28

As of the 25th of April 2024, Gross Profit is likely to grow to about 256.8 M, while Gross Profit Margin is likely to drop 0.28.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NeoGenomics Company Gross Profit Analysis

NeoGenomics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current NeoGenomics Gross Profit

187.9 M

Most of NeoGenomics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoGenomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

NeoGenomics Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for NeoGenomics is extremely important. It helps to project a fair market value of NeoGenomics Stock properly, considering its historical fundamentals such as Gross Profit. Since NeoGenomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NeoGenomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NeoGenomics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Short Term Debt	Long Term Debt	Short Term Investments	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.99	0.87	-0.69	0.5	0.99	0.99	-0.19	0.93	0.78	0.93	-0.1	0.98	0.82	0.44	0.98	0.97	0.99	0.87	0.98	0.66	0.76	0.07	0.95	0.93
Total Stockholder Equity	0.99		0.82	-0.63	0.55	0.97	0.99	-0.2	0.94	0.81	0.95	-0.09	0.95	0.84	0.52	0.96	0.94	0.98	0.85	0.97	0.69	0.74	0.16	0.96	0.91
Net Debt	0.87	0.82		-0.76	0.3	0.92	0.8	-0.15	0.78	0.56	0.74	-0.04	0.94	0.72	-0.02	0.91	0.92	0.85	0.85	0.93	0.53	0.56	-0.39	0.77	0.8
Retained Earnings	-0.69	-0.63	-0.76		-0.18	-0.75	-0.63	0.17	-0.45	-0.39	-0.67	0.1	-0.78	-0.27	0.06	-0.79	-0.81	-0.77	-0.58	-0.7	-0.41	-0.82	0.28	-0.54	-0.78
Accounts Payable	0.5	0.55	0.3	-0.18		0.42	0.52	-0.22	0.36	0.53	0.61	0.19	0.38	0.56	0.56	0.41	0.35	0.46	0.27	0.42	0.55	0.2	0.55	0.52	0.39
Total Liab	0.99	0.97	0.92	-0.75	0.42		0.97	-0.18	0.91	0.73	0.9	-0.11	1.0	0.79	0.32	0.99	0.99	0.98	0.88	0.99	0.61	0.76	-0.06	0.93	0.93
Total Current Assets	0.99	0.99	0.8	-0.63	0.52	0.97		-0.19	0.93	0.79	0.92	-0.16	0.95	0.82	0.55	0.94	0.94	0.98	0.81	0.95	0.62	0.77	0.17	0.97	0.93
Common Stock	-0.19	-0.2	-0.15	0.17	-0.22	-0.18	-0.19		-0.21	0.23	-0.31	-0.38	-0.15	-0.12	-0.1	-0.19	-0.15	-0.18	-0.2	-0.18	-0.24	-0.12	-0.07	-0.13	-0.12
Property Plant Equipment	0.93	0.94	0.78	-0.45	0.36	0.91	0.93	-0.21		0.73	0.86	-0.05	0.89	0.86	0.46	0.89	0.87	0.89	0.88	0.93	0.67	0.61	0.08	0.91	0.81
Current Deferred Revenue	0.78	0.81	0.56	-0.39	0.53	0.73	0.79	0.23	0.73		0.75	-0.23	0.71	0.8	0.57	0.72	0.7	0.77	0.59	0.74	0.68	0.59	0.34	0.8	0.72
Net Receivables	0.93	0.95	0.74	-0.67	0.61	0.9	0.92	-0.31	0.86	0.75		0.08	0.87	0.71	0.51	0.93	0.87	0.94	0.79	0.89	0.82	0.79	0.27	0.84	0.85
Short Term Debt	-0.1	-0.09	-0.04	0.1	0.19	-0.11	-0.16	-0.38	-0.05	-0.23	0.08		-0.14	-0.12	-0.2	-0.05	-0.15	-0.13	0.09	-0.08	0.28	-0.18	0.07	-0.22	-0.24
Long Term Debt	0.98	0.95	0.94	-0.78	0.38	1.0	0.95	-0.15	0.89	0.71	0.87	-0.14		0.77	0.28	0.98	0.99	0.97	0.86	0.98	0.57	0.76	-0.11	0.91	0.94
Short Term Investments	0.82	0.84	0.72	-0.27	0.56	0.79	0.82	-0.12	0.86	0.8	0.71	-0.12	0.77		0.44	0.73	0.72	0.74	0.73	0.83	0.64	0.32	0.12	0.87	0.69
Net Tangible Assets	0.44	0.52	-0.02	0.06	0.56	0.32	0.55	-0.1	0.46	0.57	0.51	-0.2	0.28	0.44		0.29	0.28	0.42	0.13	0.28	0.34	0.42	0.83	0.58	0.42
Good Will	0.98	0.96	0.91	-0.79	0.41	0.99	0.94	-0.19	0.89	0.72	0.93	-0.05	0.98	0.73	0.29		0.98	0.99	0.9	0.98	0.66	0.8	-0.05	0.88	0.92
Long Term Debt Total	0.97	0.94	0.92	-0.81	0.35	0.99	0.94	-0.15	0.87	0.7	0.87	-0.15	0.99	0.72	0.28	0.98		0.98	0.84	0.97	0.58	0.8	-0.1	0.9	0.95
Capital Surpluse	0.99	0.98	0.85	-0.77	0.46	0.98	0.98	-0.18	0.89	0.77	0.94	-0.13	0.97	0.74	0.42	0.99	0.98		0.84	0.97	0.65	0.84	0.07	0.92	0.95
Deferred Long Term Liab	0.87	0.85	0.85	-0.58	0.27	0.88	0.81	-0.2	0.88	0.59	0.79	0.09	0.86	0.73	0.13	0.9	0.84	0.84		0.92	0.57	0.57	-0.18	0.75	0.75
Intangible Assets	0.98	0.97	0.93	-0.7	0.42	0.99	0.95	-0.18	0.93	0.74	0.89	-0.08	0.98	0.83	0.28	0.98	0.97	0.97	0.92		0.65	0.7	-0.08	0.91	0.9
Short Long Term Debt	0.66	0.69	0.53	-0.41	0.55	0.61	0.62	-0.24	0.67	0.68	0.82	0.28	0.57	0.64	0.34	0.66	0.58	0.65	0.57	0.65		0.49	0.29	0.56	0.54
Net Invested Capital	0.76	0.74	0.56	-0.82	0.2	0.76	0.77	-0.12	0.61	0.59	0.79	-0.18	0.76	0.32	0.42	0.8	0.8	0.84	0.57	0.7	0.49		0.17	0.67	0.84
Long Term Investments	0.07	0.16	-0.39	0.28	0.55	-0.06	0.17	-0.07	0.08	0.34	0.27	0.07	-0.11	0.12	0.83	-0.05	-0.1	0.07	-0.18	-0.08	0.29	0.17		0.18	0.05
Net Working Capital	0.95	0.96	0.77	-0.54	0.52	0.93	0.97	-0.13	0.91	0.8	0.84	-0.22	0.91	0.87	0.58	0.88	0.9	0.92	0.75	0.91	0.56	0.67	0.18		0.93
Capital Stock	0.93	0.91	0.8	-0.78	0.39	0.93	0.93	-0.12	0.81	0.72	0.85	-0.24	0.94	0.69	0.42	0.92	0.95	0.95	0.75	0.9	0.54	0.84	0.05	0.93

Click cells to compare fundamentals

NeoGenomics Gross Profit Historical Pattern

Today, most investors in NeoGenomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NeoGenomics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's gross profit growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of NeoGenomics gross profit as a starting point in their analysis.

NeoGenomics Gross Profit

Timeline

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict NeoGenomics

Gross Profit Over Time

According to the company disclosure, NeoGenomics reported 187.9 M of gross profit. This is 91.62% lower than that of the Life Sciences Tools & Services sector and 78.97% lower than that of the Health Care industry. The gross profit for all United States stocks is 99.31% higher than that of the company.

NeoGenomics Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoGenomics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics of similar companies.

NeoGenomics is currently under evaluation in gross profit category among related companies.

NeoGenomics Fundamentals

	Return On Equity	-0.0907
	Return On Asset	-0.035
	Profit Margin	(0.15) %
	Operating Margin	(0.11) %
	Current Valuation	1.91 B
	Shares Outstanding	127.67 M
	Shares Owned By Insiders	1.18 %
	Shares Owned By Institutions	98.82 %
	Number Of Shares Shorted	7.24 M
	Price To Earning	272.37 X
	Price To Book	1.91 X
	Price To Sales	3.04 X
	Revenue	591.64 M
	Gross Profit	187.9 M
	EBITDA	(6.52 M)
	Net Income	(87.97 M)
	Cash And Equivalents	465.95 M
	Cash Per Share	3.70 X
	Total Debt	611.68 M
	Debt To Equity	0.59 %
	Current Ratio	7.53 X
	Book Value Per Share	7.39 X
	Cash Flow From Operations	(1.95 M)
	Short Ratio	9.07 X
	Earnings Per Share	(0.70) X
	Price To Earnings To Growth	3.02 X
	Target Price	21.55
	Number Of Employees	2.1 K
	Beta	1.1
	Market Capitalization	1.81 B
	Total Asset	1.68 B
	Retained Earnings	(247.06 M)
	Working Capital	500.51 M
	Current Asset	82.36 M
	Current Liabilities	40.06 M
	Net Asset	1.68 B

About NeoGenomics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NeoGenomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

NeoGenomics Investors Sentiment

The influence of NeoGenomics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in NeoGenomics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to NeoGenomics' public news can be used to forecast risks associated with an investment in NeoGenomics. The trend in average sentiment can be used to explain how an investor holding NeoGenomics can time the market purely based on public headlines and social activities around NeoGenomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

NeoGenomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for NeoGenomics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average NeoGenomics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on NeoGenomics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NeoGenomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NeoGenomics' short interest history, or implied volatility extrapolated from NeoGenomics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:

How To Invest In NeoGenomics

Details

Is NeoGenomics Stock a good investment?

Details

What is NeoGenomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out NeoGenomics Piotroski F Score and NeoGenomics Altman Z Score analysis.

To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.

Note that the NeoGenomics information on this page should be used as a complementary analysis to other NeoGenomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for NeoGenomics Stock analysis

When running NeoGenomics' price analysis, check to measure NeoGenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoGenomics is operating at the current time. Most of NeoGenomics' value examination focuses on studying past and present price action to predict the probability of NeoGenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoGenomics' price. Additionally, you may evaluate how the addition of NeoGenomics to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators

Is NeoGenomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.306

Earnings Share

(0.70)

Revenue Per Share

4.714

Quarterly Revenue Growth

0.121

Return On Assets

(0.04)

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neogenomics Stock Gross Profit

NeoGenomics Company Gross Profit Analysis

Gross Profit

Revenue

-

Cost of Revenue

Current NeoGenomics Gross Profit

NeoGenomics Gross Profit Driver Correlations

NeoGenomics Gross Profit Historical Pattern

NeoGenomics Gross Profit Peer Comparison

NeoGenomics Fundamentals

About NeoGenomics Fundamental Analysis

NeoGenomics Investors Sentiment

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for NeoGenomics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY